Amgen resolves lawsuit with FTC regarding Horizon acquisition

The US Federal Trade Commission today announced it has reached a
proposed consent order with Amgen (Nasdaq: AMGN) to address what
the agency saw as potential competitive harm that would result
from the biotech major’s $27.8 billion
acquisition of Horizon Therapeutics (Nasdaq: HZNP). 

News of the resolution moved Horizon’s shares move up a modest
2.5% to $115.56, while Amgen stock was barely changed.

As part of a nationwide settlement…

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

• All the news that moves the needle in pharma and biotech.
• Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
• Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

• Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
• Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
• Daily roundup of key events in pharma and biotech.
• Monthly in-depth briefings on Boardroom appointments and M&A news.
• Choose from a cost-effective annual package or a flexible monthly subscription.

No Byline Policy

Editorial Guidelines

Corrections Policy

Source